Eupraxia Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Eupraxia Pharmaceuticals has a total shareholder equity of $8.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $10.4M and $2.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$8.66m |
| Equity | US$7.98m |
| Total liabilities | US$2.39m |
| Total assets | US$10.36m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EPRX's short term assets ($9.9M) exceed its short term liabilities ($2.4M).
Long Term Liabilities: EPRX's short term assets ($9.9M) exceed its long term liabilities ($14.3K).
Debt to Equity History and Analysis
Debt Level: EPRX is debt free.
Reducing Debt: EPRX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EPRX has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: EPRX is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.